Sandoz management is preparing to set out detailed plans for the soon-to-be standalone company at a capital markets day on 8 June, as the firm gets closer to being spun off from parent company Novartis.
With industry onlookers eager to learn more about the generics and biosimilars specialist’s future plans, Generics Bulletin traces the path that has brought Sandoz to this point – as well as
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?